These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 22885699)

  • 1. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
    Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
    Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
    Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
    Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis?
    Soldini D; Campo E
    Expert Rev Hematol; 2013 Jun; 6(3):219-21. PubMed ID: 23782073
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncogenic mechanisms in Burkitt lymphoma.
    Schmitz R; Ceribelli M; Pittaluga S; Wright G; Staudt LM
    Cold Spring Harb Perspect Med; 2014 Feb; 4(2):. PubMed ID: 24492847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sporadic and endemic Burkitt lymphoma have frequent
    Zhou P; Blain AE; Newman AM; Zaka M; Chagaluka G; Adlar FR; Offor UT; Broadbent C; Chaytor L; Whitehead A; Hall A; O'Connor H; Van Noorden S; Lampert I; Bailey S; Molyneux E; Bacon CM; Bomken S; Rand V
    Blood Adv; 2019 Jul; 3(14):2118-2127. PubMed ID: 31300419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
    Richter J; John K; Staiger AM; Rosenwald A; Kurz K; Michgehl U; Ott G; Franzenburg S; Kohler C; Finger J; Oschlies I; Paul U; Siebert R; Spang R; Burkhardt B; Klapper W
    Br J Haematol; 2022 Feb; 196(3):681-689. PubMed ID: 34617271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burkitt lymphoma-related
    Yamazaki T; Liu L; Conlon EG; Manley JL
    RNA Biol; 2020 Oct; 17(10):1383-1390. PubMed ID: 32449435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
    Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
    Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
    Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas.
    Soldini D; Georgis A; Montagna C; Schüffler PJ; Martin V; Curioni-Fontecedro A; Martinez A; Tinguely M
    Hematol Oncol; 2014 Sep; 32(3):120-5. PubMed ID: 24493312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features.
    Sureda-Gómez M; Iaccarino I; De Bolòs A; Meyer M; Balsas P; Richter J; Rodríguez ML; López C; Carreras-Caballé M; Glaser S; Nadeu F; Jares P; Clot G; Siciliano MC; Bellan C; Tornambè S; Boccacci R; Leoncini L; Campo E; Siebert R; Amador V; Klapper W
    Blood; 2024 Jul; 144(2):187-200. PubMed ID: 38620074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.
    Corso J; Pan KT; Walter R; Doebele C; Mohr S; Bohnenberger H; Ströbel P; Lenz C; Slabicki M; Hüllein J; Comoglio F; Rieger MA; Zenz T; Wienands J; Engelke M; Serve H; Urlaub H; Oellerich T
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5688-93. PubMed ID: 27155012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
    Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N; Bernard V; Feller AC; Merz H
    Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.
    Zayac AS; Olszewski AJ
    Leuk Lymphoma; 2020 Aug; 61(8):1784-1796. PubMed ID: 32255708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.
    Walter R; Pan KT; Doebele C; Comoglio F; Tomska K; Bohnenberger H; Young RM; Jacobs L; Keller U; Bönig H; Engelke M; Rosenwald A; Urlaub H; Staudt LM; Serve H; Zenz T; Oellerich T
    Blood; 2017 Feb; 129(5):598-608. PubMed ID: 28064214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
    Amato T; Abate F; Piccaluga P; Iacono M; Fallerini C; Renieri A; De Falco G; Ambrosio MR; Mourmouras V; Ogwang M; Calbi V; Rabadan R; Hummel M; Pileri S; Leoncini L; Bellan C
    Am J Clin Pathol; 2016 Jan; 145(1):116-27. PubMed ID: 26712879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.